BioWorld

Aug. 31, 2006

Genzyme Wants AnorMed For $380M; AnorMed Uninterested

After AnorMed Inc.'s board rejected an unsolicited $380 million takeover bid, Genzyme Corp. said it plans to go to AnorMed shareholders with a proposal to acquire the company. (BioWorld Today) Read More

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint

P38 MAP Kinase Block May Foil One More Autoimmune Disorder

Roche Returns Zenapax Rights In Asthma To PDL

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...